In a recent development, the prominent investment firm HC Wainwright & Co. has adjusted its price target for Biogen (BIIB, Financial), a leading biotechnology company. Analyst Andrew Fein has maintained the 'Buy' rating for the stock but lowered the price target from $241.00 to $187.00 USD. This represents a significant decrease of 22.41% from the previous target.
The revision in the price target reflects current market evaluations and strategic outlooks surrounding Biogen (BIIB, Financial). Despite the lowered price target, the maintained 'Buy' rating indicates continued confidence in the company's potential growth and investment value.
As of May 2, 2025, this adjustment is notable among several market analyses and serves as an important indicator for investors monitoring Biogen's (BIIB, Financial) performance and future projections in the biotechnology sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Biogen Inc (BIIB, Financial) is $180.15 with a high estimate of $300.00 and a low estimate of $115.00. The average target implies an upside of 48.97% from the current price of $120.93. More detailed estimate data can be found on the Biogen Inc (BIIB) Forecast page.
Based on the consensus recommendation from 37 brokerage firms, Biogen Inc's (BIIB, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Biogen Inc (BIIB, Financial) in one year is $211.68, suggesting a upside of 75.04% from the current price of $120.93. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Biogen Inc (BIIB) Summary page.
